Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Thrombocythemia, Essential 1Rhabdoid Tumor 1Polycythemia Vera 1Multiple Myeloma 1Glioblastoma 1Chromosome 17 deletion 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Temozolomide 64Radiotherapy 53Filgrastim 28Carboplatin 24Etoposide 20Irinotecan 17Vincristine 16Cyclophosphamide 16Cisplatin 15Carmustine 14Peripheral Blood Stem Cell Transplantation 13Magnetic Resonance Spectroscopy 12Bevacizumab 12Thiotepa 11Thalidomide 11Chemotherapy, Adjuvant 11Methotrexate 10Paclitaxel 9Granulocyte Colony-Stimulating Factor 9etoposide phosphate 8Surgical Procedures, Operative 8Procarbazine 8Ifosfamide 8sargramostim 7Topotecan 7O(6)-benzylguanine 7Lomustine 7Busulfan 7Radiation 6Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Central Nervous System Neoplasms × RG7388 × Clear all
NCT05952687 2024-03-27

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

St. Jude Children's Research Hospital

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡